Cadisegliatin (TTP399)

About vTv Therapeutics

vTv Therapeutics is a clinical-stage biotech focused on developing oral small-molecule drugs for chronic diseases, with its entire strategy anchored on cadisegliatin, a liver-selective glucokinase activator for Type 1 Diabetes (T1D). The company's mission is to address the significant unmet need in T1D by providing an oral adjunct to insulin that improves glycemic control without increasing hypoglycemia risk. Its achievement rests on advancing this novel mechanism into a pivotal Phase 3 trial (Simplici-T1), with the strategic goal of securing regulatory approval and capturing a first-mover advantage in a large, underserved market. vTv's future is intrinsically tied to the success or failure of this single, late-stage asset.

Therapeutic Areas